ID

31715

Descrizione

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT00741819

collegamento

https://clinicaltrials.gov/show/NCT00741819

Keywords

versioni (1)
  1. 22/09/18 22/09/18 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

22 settembre 2018

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Pulmonary Arterial Hypertension NCT00741819

Inglese

Eligibility Pulmonary Arterial Hypertension NCT00741819

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
between 18 and 75 years of age
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
pah diagnosis defined by following who group i categories: idiopathic/familial, associated with unrepaired or repaired congenital systemic-to-pulmonary shunts (repaired >/= 5 years), associated with collagen vascular disease, associated with hiv, associated with appetite suppressant/toxin use
Descrizione

Pulmonary arterial hypertension WHO classification | Idiopathic pulmonary arterial hypertension | Familial pulmonary arterial hypertension | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt Repaired | Pulmonary arterial hypertension Associated with Collagen-vascular disease | Pulmonary arterial hypertension associated with HIV infection | Pulmonary arterial hypertension Associated with Appetite Depressants | Pulmonary arterial hypertension Associated with Use of Toxin

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2973725
UMLS CUI [1,2]
C4267671
UMLS CUI [2]
C3203102
UMLS CUI [3]
C1701939
UMLS CUI [4]
C3698160
UMLS CUI [5,1]
C3698160
UMLS CUI [5,2]
C0205340
UMLS CUI [6,1]
C2973725
UMLS CUI [6,2]
C0332281
UMLS CUI [6,3]
C0262428
UMLS CUI [7]
C3697673
UMLS CUI [8,1]
C2973725
UMLS CUI [8,2]
C0332281
UMLS CUI [8,3]
C0003620
UMLS CUI [9,1]
C2973725
UMLS CUI [9,2]
C0332281
UMLS CUI [9,3]
C1524063
UMLS CUI [9,4]
C0040549
baseline six-minute walk distance (6mwd) >/= 250 meters
Descrizione

6-Minute Walk Test Meter Quantity

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0430515
UMLS CUI [1,2]
C0475209
UMLS CUI [1,3]
C1265611
currently receiving ventavis and be stable at current dose for 30 days prior to baseline
Descrizione

Ventavis Dose Stable

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1541936
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C0205360
if currently receiving other approved background therapy (i.e. endothelin receptor antagonist or phosphodiesterase-5-inhibitor or both) must be on stable dose for 30 days prior to baseline
Descrizione

Background Therapy Dose Stable | Endothelin receptor antagonist Dose Stable | Phosphodiesterase 5 inhibitor Dose Stable

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1706907
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C0178602
UMLS CUI [1,4]
C0205360
UMLS CUI [2,1]
C1134681
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
UMLS CUI [3,1]
C1318700
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205360
previous testing (e.g. right heart catheterization, echocardiography) consistent with diagnosis of pah
Descrizione

Testing Consistent with Pulmonary arterial hypertension | Catheterization of right heart | Echocardiography

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0039593
UMLS CUI [1,2]
C0332290
UMLS CUI [1,3]
C2973725
UMLS CUI [2]
C0189896
UMLS CUI [3]
C0013516
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
nursing or pregnant
Descrizione

Breast Feeding | Pregnancy

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0006147
UMLS CUI [2]
C0032961
has acute concomitant disease (e.g. portal hypertension, chronic thromboembolic disease, pulmonary veno-occlusive disease, etc) other than those accepted as part of the inclusion criteria or has had atrial septostomy
Descrizione

Comorbidity Except Inclusion criteria | Hypertension, Portal | Thromboembolism chronic | Pulmonary Veno-Occlusive Disease | Atrial septostomy

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0332300
UMLS CUI [1,3]
C1512693
UMLS CUI [2]
C0020541
UMLS CUI [3,1]
C0040038
UMLS CUI [3,2]
C0205191
UMLS CUI [4]
C0034091
UMLS CUI [5]
C0397233
history of uncontrolled sleep apnea, left-sided heart disease, or parenchymal lung disease
Descrizione

Sleep Apnea Uncontrolled | Heart Disease Left sided Uncontrolled | Lung disease Parenchymal Uncontrolled

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0037315
UMLS CUI [1,2]
C0205318
UMLS CUI [2,1]
C0018799
UMLS CUI [2,2]
C0443246
UMLS CUI [2,3]
C0205318
UMLS CUI [3,1]
C0024115
UMLS CUI [3,2]
C4277702
UMLS CUI [3,3]
C0205318
use of investigational drug within 30 days of baseline
Descrizione

Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
Ritorna all'inizio della pagina

Similar models

Eligibility Pulmonary Arterial Hypertension NCT00741819

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
between 18 and 75 years of age
boolean
C0001779 (UMLS CUI [1])
Pulmonary arterial hypertension WHO classification | Idiopathic pulmonary arterial hypertension | Familial pulmonary arterial hypertension | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt | Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunt Repaired | Pulmonary arterial hypertension Associated with Collagen-vascular disease | Pulmonary arterial hypertension associated with HIV infection | Pulmonary arterial hypertension Associated with Appetite Depressants | Pulmonary arterial hypertension Associated with Use of Toxin
Item
pah diagnosis defined by following who group i categories: idiopathic/familial, associated with unrepaired or repaired congenital systemic-to-pulmonary shunts (repaired >/= 5 years), associated with collagen vascular disease, associated with hiv, associated with appetite suppressant/toxin use
boolean
C2973725 (UMLS CUI [1,1])
C4267671 (UMLS CUI [1,2])
C3203102 (UMLS CUI [2])
C1701939 (UMLS CUI [3])
C3698160 (UMLS CUI [4])
C3698160 (UMLS CUI [5,1])
C0205340 (UMLS CUI [5,2])
C2973725 (UMLS CUI [6,1])
C0332281 (UMLS CUI [6,2])
C0262428 (UMLS CUI [6,3])
C3697673 (UMLS CUI [7])
C2973725 (UMLS CUI [8,1])
C0332281 (UMLS CUI [8,2])
C0003620 (UMLS CUI [8,3])
C2973725 (UMLS CUI [9,1])
C0332281 (UMLS CUI [9,2])
C1524063 (UMLS CUI [9,3])
C0040549 (UMLS CUI [9,4])
6-Minute Walk Test Meter Quantity
Item
baseline six-minute walk distance (6mwd) >/= 250 meters
boolean
C0430515 (UMLS CUI [1,1])
C0475209 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Ventavis Dose Stable
Item
currently receiving ventavis and be stable at current dose for 30 days prior to baseline
boolean
C1541936 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
Background Therapy Dose Stable | Endothelin receptor antagonist Dose Stable | Phosphodiesterase 5 inhibitor Dose Stable
Item
if currently receiving other approved background therapy (i.e. endothelin receptor antagonist or phosphodiesterase-5-inhibitor or both) must be on stable dose for 30 days prior to baseline
boolean
C1706907 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0205360 (UMLS CUI [1,4])
C1134681 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C1318700 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
Testing Consistent with Pulmonary arterial hypertension | Catheterization of right heart | Echocardiography
Item
previous testing (e.g. right heart catheterization, echocardiography) consistent with diagnosis of pah
boolean
C0039593 (UMLS CUI [1,1])
C0332290 (UMLS CUI [1,2])
C2973725 (UMLS CUI [1,3])
C0189896 (UMLS CUI [2])
C0013516 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Breast Feeding | Pregnancy
Item
nursing or pregnant
boolean
C0006147 (UMLS CUI [1])
C0032961 (UMLS CUI [2])
Comorbidity Except Inclusion criteria | Hypertension, Portal | Thromboembolism chronic | Pulmonary Veno-Occlusive Disease | Atrial septostomy
Item
has acute concomitant disease (e.g. portal hypertension, chronic thromboembolic disease, pulmonary veno-occlusive disease, etc) other than those accepted as part of the inclusion criteria or has had atrial septostomy
boolean
C0009488 (UMLS CUI [1,1])
C0332300 (UMLS CUI [1,2])
C1512693 (UMLS CUI [1,3])
C0020541 (UMLS CUI [2])
C0040038 (UMLS CUI [3,1])
C0205191 (UMLS CUI [3,2])
C0034091 (UMLS CUI [4])
C0397233 (UMLS CUI [5])
Sleep Apnea Uncontrolled | Heart Disease Left sided Uncontrolled | Lung disease Parenchymal Uncontrolled
Item
history of uncontrolled sleep apnea, left-sided heart disease, or parenchymal lung disease
boolean
C0037315 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0018799 (UMLS CUI [2,1])
C0443246 (UMLS CUI [2,2])
C0205318 (UMLS CUI [2,3])
C0024115 (UMLS CUI [3,1])
C4277702 (UMLS CUI [3,2])
C0205318 (UMLS CUI [3,3])
Investigational New Drugs
Item
use of investigational drug within 30 days of baseline
boolean
C0013230 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial